Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 473 All time
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| VM Virchow MedicalCompany profile Provides biopsy specimen stewardship and expands access to precision oncology Provides biopsy specimen stewardship and expands access to precision oncology | $4M | Seed | Biotech, Healthtech | United States | Investors | |
| GP Gilgamesh PharmaCompany profile Develops novel chemical entities for psychiatric and neurological disorders Develops novel chemical entities for psychiatric and neurological disorders | $60M | Series A | Biotech | United States | Investors | |
| R RyboDynCompany profile Decodes the dark proteome using an AI-powered novel sequencing and discovery platform to reveal novel cancer targets Decodes the dark proteome using an AI-powered novel sequencing and discovery platform to reveal novel cancer targets | $10M | Seed | Biotech | United States | Investors | |
| N NanoZymeXCompany profile NanoZymeX develops a lipid-nanoparticle platform for enzyme replacement therapy. NanoZymeX develops a lipid-nanoparticle platform for enzyme replacement therapy. | €160K | Pre-SeedPre-seed | Biotech | Switzerland | Investors | |
| ET Develops novel therapies for beta globin disorders | $32M | GrantUndisclosed | Biotech | United States | Investors | |
| AT Amani TherapeuticsCompany profile Biotechnology company developing combination medicines for serious neuropsychiatric disorders. Biotechnology company developing combination medicines for serious neuropsychiatric disorders. | $25M | Series A | Biotech | United States | Investors | |
| OC Oryon Cell TherapiesCompany profile Develops autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders Develops autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders | $21M | Series A | Biotech | United States | Investors | |
| CT Congruence TherapeuticsCompany profile Develops small molecule correctors for diseases of protein misfolding Develops small molecule correctors for diseases of protein misfolding | $39.5M | Series B | Biotech | Canada | Investors | |
| HU Health UniverseCompany profile Provides AI infrastructure for healthcare organizations to integrate and govern autonomous agents Provides AI infrastructure for healthcare organizations to integrate and govern autonomous agents | $6M | Seed | Biotech, Healthtech | United States | Investors | |
| EL Elea & LiliCompany profile Commercialises cellulose-based biodegradable absorbent materials for hygiene and agriculture Commercialises cellulose-based biodegradable absorbent materials for hygiene and agriculture | €2.5M | Seed | Biotech, Climate tech | Finland | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →